Last reviewed 2026-04-22 · How we verify

low immunogenic interferon-beta-1a

Low immunogenic interferon-beta-1a activates interferon-beta signaling pathways to modulate immune responses and reduce inflammation in autoimmune diseases.

Low immunogenic interferon-beta-1a activates interferon-beta signaling pathways to modulate immune responses and reduce inflammation in autoimmune diseases. Used for Relapsing-remitting multiple sclerosis, Secondary progressive multiple sclerosis.

At a glance

Mechanism of action

Interferon-beta-1a binds to interferon-beta receptors on immune cells, triggering intracellular signaling cascades that enhance natural killer cell activity, increase antiviral and anti-inflammatory cytokine production, and shift T-cell differentiation toward regulatory phenotypes. The 'low immunogenic' formulation is designed to minimize the formation of neutralizing antibodies against the interferon-beta protein, thereby maintaining therapeutic efficacy over time.

Approved indications

• Relapsing-remitting multiple sclerosis
• Secondary progressive multiple sclerosis

Common side effects

• Flu-like symptoms (fever, chills, myalgia)
• Injection site reactions
• Headache
• Elevated liver enzymes
• Leukopenia
• Depression

Key clinical trials

• Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• low immunogenic interferon-beta-1a CI brief — competitive landscape report
• low immunogenic interferon-beta-1a updates RSS · CI watch RSS
• Biogen portfolio CI